Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti‐TNF therapy
- 15 June 2015
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 42 (4) , 391-405
Abstract
Summary: Background: The discontinuation of anti‐tumour necrosis factor (anti‐TNF) treatment in inflammatory bowel disease (IBD) patients in remission could be considered.Aim: To evaluate the factors associated with relapse of IBD after discontinuation of anti‐TNF therapy.Methods: Electronic (PubMed/Embase) and manual search up to January 2015.Results: The overall risk of relapse after discontinuation of anti‐TNFs (27 studies) was 44% for Crohn's disease (CD; follow‐up range: 6–125 months) and 38% for ulcerative colitis (follow‐up range: 6–24 months). Several factors were investigated to identify patients who are more likely to achieve long‐lasting remission after anti‐TNF discontinuation. The factors associated with a higher risk of relapse are younger age, smoking, longer disease duration, and fistulising perianal CD. Laboratory markers such as low haemoglobin levels, high C‐reactive protein levels and high faecal calprotectin seem to increase the risk of relapse. On the other hand, low serum anti‐TNF levels seem to be associated with a lower risk of flare‐up. Mucosal healing seems to decrease the risk of relapse after anti‐TNF discontinuation (overall, this risk is 26% at 1 year with mucosal healing and 42% without), although this observation has not been confirmed by some authors. In patients receiving escalated anti‐TNF doses or receiving anti‐TNFs for the prevention of post‐operative CD recurrence, the risk of relapse after discontinuation is high (>75%). Re‐administration of the drug in those who relapsed after stopping treatment is effective and safe.Conclusions: A high proportion of patients with IBD relapse after discontinuation of anti‐TNF treatment. As available data are insufficient to make strong recommendations on when anti‐TNF therapy could be stopped, decisions should be taken on an individual basis.Keywords
This publication has 80 references indexed in Scilit:
- Management of Postoperative Recurrence of Crohn's DiseaseDigestive Diseases, 2013
- Smoking does influence disease behaviour and impacts the need for therapy in Crohn′s disease in the biologic eraAlimentary Pharmacology & Therapeutics, 2013
- P.02.11 WITHDRAWAL OF INFLIXIMAB (IFX) AFTER ACHIEVING REMISSION: OUTCOME IN A COHORT OF INFLAMMATORY BOWEL DISEASE (IBD) PATIENTSDigestive and Liver Disease, 2013
- Effects of Discontinuing Anti–Tumor Necrosis Factor Therapy During Pregnancy on the Course of Inflammatory Bowel Disease and Neonatal ExposureClinical Gastroenterology and Hepatology, 2013
- A prospective study of infliximab withdrawal after 12 months of treatment in patients with Crohn’s disease: how will NICE guidance affect patient care?Clinical Medicine, 2012
- Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center studyScandinavian Journal of Gastroenterology, 2012
- Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) studyAnnals of the Rheumatic Diseases, 2010
- Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn’s disease with anal endosonographic monitoring: a single-centre experienceTechniques in Coloproctology, 2008
- Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM TrialGastroenterology, 2007
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002